Siltanen has also produced a company report 
Orion published on Wednesday its outlook for 2026 and an estimate of the revenue potential for its blockbuster prostate cancer drug Nubeqa. The guidance exceeded our expectations in terms of revenue, and the midpoint of the earnings guidance is also higher than our forecasts. Additionally, the company specified Nubeqa’s long-term revenue potential to over EUR 1 billion. The potential is in line with our forecasts (2030). The market rewarded shareholders with a sharp rise in the share price. We are raising our forecasts following the new information. Corresponding to the forecast hikes, we raise our target price to EUR 75 (prev. 66) and reiterate our Accumulate recommendation.